← Back to papers

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

★ ★ ★ ★ ☆

Overview

Paper Summary › Explain Like I'm Five › Conflicts of Interest › Identified Limitations › Rating Explanation › Good to know › Topic Hierarchy › File Information ›

Paper Summary

Paperzilla title
Keeping Hearts Pumping While Fighting Cancer: A Cardio-Oncology Guide

These guidelines address cardiovascular care for cancer patients before, during, and after treatment, focusing on prevention, surveillance, and management of cancer therapy-related cardiovascular toxicity. They recommend baseline risk assessment, personalized surveillance protocols, and management strategies for various cancer therapies and cardiovascular conditions, emphasizing a multidisciplinary approach and patient involvement in care.

Explain Like I'm Five

Scientists found that cancer treatments can sometimes hurt your heart. So, doctors made new rules to help make sure your heart stays strong and healthy before, during, and after you get medicine for cancer.

Possible Conflicts of Interest

The task force received financial support from the ESC without industry involvement. Experts submitted declarations of interest, which were reviewed and published in a supplementary document available on the ESC website.

Identified Limitations

Limited Evidence Base
The guideline acknowledges limitations in available evidence for many recommendations, with some based on expert opinion due to the lack of robust trials.
Dynamic Nature of Evidence
The guideline is based on evidence available at the time of writing and may require updates due to the rapidly evolving oncology landscape and new treatment developments.
Implementation Challenges
The guideline emphasizes personalized approaches to care, which can be challenging to implement consistently across diverse healthcare settings and patient populations.
Limited Validation of Risk Stratification
The guideline relies on risk stratification methods that have not been extensively validated in all cancer types and patient populations.
Gaps in Research
The guideline acknowledges the need for more research in various areas, including long-term surveillance, optimal treatment strategies, and underlying mechanisms connecting CVD and cancer.

Rating Explanation

This guideline provides valuable, comprehensive guidance for managing cardiovascular health in cancer patients, encompassing risk assessment, surveillance, prevention, and treatment of cardiovascular complications. It promotes a multidisciplinary approach and emphasizes personalized care, although further research and validation are needed in several areas.

Good to know

This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.

Explore Pro →

Topic Hierarchy

Domain: Health Sciences
Field: Medicine
Subfield: Cardiology and Cardiovascular Medicine

File Information

Original Title: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Uploaded: July 14, 2025 at 05:17 PM
Privacy: Public